0 Comments
0 Shares
513 Views
0 Reviews
Search
Discover new people, create new connections and make new friends
-
Please log in to like, share and comment!
-
Digihaler SF 250 Inhaler – Effective Asthma and COPD TreatmentDigihaler SF 250 Inhaler is a trusted medication used for the effective management of asthma and chronic obstructive pulmonary disease (COPD). It helps patients breathe easier by relaxing the airway muscles and improving airflow to the lungs. The inhaler contains two active ingredients – Salmeterol and Fluticasone Propionate. Salmeterol acts as a long-acting bronchodilator that...0 Comments 0 Shares 388 Views 0 Reviews
-
Exosomes for Chronic Obstructive Pulmonary Disease (COPD)Question: Can exosome-based interventions reverse the inflammatory progression of COPD? Answer: COPD involves chronic airway inflammation and emphysema often triggered by cigarette smoke or environmental pollutants. Therapeutic exosomes, particularly those derived from immunomodulatory cells, have shown the ability to suppress the infiltration of neutrophils and macrophages in the lungs....0 Comments 0 Shares 110 Views 0 Reviews
-
ForAir 250 CFC Free Inhaler | Asthma & COPD Maintenance TherapyForAir 250 CFC Free Inhaler is a prescription inhalation medicine commonly used for the long-term management of asthma and chronic obstructive pulmonary disease (COPD). It contains a combination of formoterol and fluticasone propionate, which work together to help reduce airway inflammation and relax the muscles around the airways. This dual action supports better breathing control and...0 Comments 0 Shares 640 Views 0 Reviews
-
How Is Innovation Reshaping the Global Respiratory Inhalers Market?Key Drivers Impacting Executive Summary Respiratory Inhalers Market Market Size and Share CAGR Value The global respiratory inhalers market size was valued at USD 36.44 billion in 2024 and is expected to reach USD 57.52 billion by 2032, at a CAGR of 5.87% during the forecast period The report explains the vital developments about the Respiratory...0 Comments 0 Shares 125 Views 0 Reviews